Next Article in Journal
Transcriptional Analysis of Apoptotic Cerebellar Granule Neurons Following Rescue by Gastric Inhibitory Polypeptide
Previous Article in Journal
Silencing of Ether à Go-Go 1 by shRNA Inhibits Osteosarcoma Growth and Cell Cycle Progression
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 15
Issue 4
10.3390/ijms15045582
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Synthesis and Anti-Breast Cancer Evaluation of Novel N-(Guanidinyl)benzenesulfonamides

by
Mostafa M. Ghorab
1,*,
Marwa G. El-Gazzar
2 and
Mansour S. Alsaid
1
1
Department of Pharmacognosy, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia
2
Department of Drug Radiation Research, National Center for Radiation Research and Technology, Nasr City, Cairo 11371, Egypt
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2014, 15(4), 5582-5595; https://doi.org/10.3390/ijms15045582
Submission received: 23 February 2014 / Revised: 19 March 2014 / Accepted: 20 March 2014 / Published: 1 April 2014
(This article belongs to the Section Biochemistry)
Browse Figures
Versions Notes

Abstract

:
A series of 4-(substituted)-N-(guanidinyl)benzenesulfonamides bearing biologically active pyrazole, pyrimidine and pyridine moieties were prepared and evaluated for their anticancer activity against human tumor breast cell line (MCF7). These sulfonamides showed promising activity with IC50 values ranging from 49.5 to 70.2 μM. The structure-activity relationship of the synthesized compounds was studied. Interestingly, it was found that the most potent compounds in this study were the corresponding 2-cyanoacrylate 3, 3-oxobutanoate 4, pyrazole 6, pyridine 9 and pyrazole 13. Compounds 7 and 8 are nearly as active as Doxorubicin as reference drug with (IC50 values = 70.2, 68.1 μM), while compounds 5, 10 and 11 exhibited a moderate activity.

1. Introduction

Cancer, known medically as malignant neoplasia, is a broad group of diseases involving unregulated cell growth. In cancer, cells divide and grow uncontrollably, forming malignant tumors, which may invade nearby parts of the body. The cancer may also spread to more distant parts of the body through the lymphatic system or bloodstream [1,2]. Breast cancer is a kind of cancer that develops from breast cells. Breast cancer usually starts off in the inner lining of milk ducts or the lobules that supply them with milk. A malignant tumor can spread to other parts of the body [3,4]. The vast majority of breast cancer cases occur in females and breast cancer is the most common invasive cancer in females worldwide. It accounts for 16% of all female cancers and 22.9% of invasive cancers in women. Including both males and females, 18.2% of all cancer deaths worldwide are from breast cancer [5,6]. Treatments for breast cancer include surgery as well as radiation, chemotherapy and hormonal therapy; these treatments are either local or systemic. Local treatments, such as surgery and radiation therapy, remove, destroy or control cancer cells in specific areas. Systemic treatments, such as chemotherapy and hormonal therapy, destroy or control cancer throughout the body. Depending on the condition, one may receive one treatment or a combination at the same time or in succession [7].
Nitrogen heterocycles are of special interest because they constitute an important class of natural and non-natural products, many of which exhibit useful biological activities. Pyrazoles and their derivatives exhibit a broad spectrum of biological activities such as antimicrobial [8], anti-inflammatory [9], and antitumor activities [10]. With growing application on their synthesis and bioactivity, chemists and biologists in recent years have directed considerable attention on the research of pyrazole derivatives. Pyrimidines are of chemical and pharmacological interest and compounds containing the pyrimidine ring system have been shown to possess antimicrobial [11,12], antimalarial [13], anticonvulsant [14], and antitumor activities [15]. Some are valuable drugs for the treatment of acute leukemia in children and adult granulocytic leukemia [16]. Compounds containing a pyridine moiety as a precursor have proven to possess several biologically properties especially as anticancer agents [17–19]. These findings led us to enlarge our investigations and to continue working on the synthesis of biologically active compounds [20–25] to synthesize a series of 4-(substituted)-N-(guanidinyl)benzenesulfonamides in order to evaluate if the presence of the guanidine moiety could enhance their biological activities. The choice of guanidine derivatives is due to its presence in several classes of pharmacological active compounds, recently anticancer drugs [26,27], and also in some commercially available drugs for example, the anti-diabetic metformin which is an oral anti-diabetic drug in the biguanide class and the first-line drug of choice for the treatment of type 2 diabetes [28–30]; the anticoagulant Nafamostatmesilate [31]; cimetidine which is a histamine H2-receptor antagonist that inhibits stomach acid production and largely used in the treatment of heartburn and peptic ulcers [32]. Gabexate is a serine protease inhibitor which is used therapeutically (as Gabexatemesilate) in the treatment of pancreatitis, and disseminated intravascular coagulation [33] (Figure 1).

2. Results and Discussion

2.1. Chemistry

In this work, the reactivity of sulfaguanidine1 with active methylenes (malononitril, 2-(ethoxymethylene)malononitrile, ethylcyanoacetate, (ethoxymethylene)ethylcyanoacetate, ethylacetoacetate and acetylacetone) was studied. The reactions proceeded according to the reported method [24] and the obtained sulfonamide derivatives 2–5, respectively, were identified by elemental and spectral data (Scheme 1). Due to the biological importance of pyrazole, pyridine and pyrimidine rings as anticancer agents, the strategic starting materials sulfonamide derivatives 2 and 5 were reacted with different nucleophiles in order to obtain biologically active pyrazole, pyridine and pyrimidine derivatives bearing sulfonamide moieties. Thus, interaction of sulfonamide derivatives 2 with either hydrazine hydrate or methylhydrazine yielded the corresponding pyrazole derivatives 6 and 7, the formation of the pyrazole ring was proved by the disappearance of CN in the infrared spectra and the appearance of NH2 bands which is also traced in their 1H-NMR spectra and were exchangeable with D2O, 1H-NMR spectrum of compound 7 showed a singlet at 2.4 ppm corresponding to the methyl group, while, their 13C-NMR spectra showed the appearance of signals for the carbons of the pyrazole rind at 166.4 ppm for compound 6 and 163.8 ppm for compound 7. On the other hand, interaction of compound 2 with chloroacetyl chloride in dioxane as a solvent containing triethylamine as catalyst yielded the corresponding pyridine derivatives 9 which was characterized by the presence of CN band and appearance of new bands for NH2, carbonyl and C-Clgroups in the infrared spectrum and the specific signals of the pyridine ring appeared in the 13C-NMR spectrum. Reaction of compound 2 with phenyl isothiocyanate in NaOH/ethanol and/or thiourea gave the corresponding pyrimidine-2-thione derivatives 8 or 10, respectively and their structure were proved by microanalytical and spectral data (Scheme 2). Similarily, the sulfonamide derivative 5 was reacted with either hydrazine hydrate, methylhydrazine or phenylhydrazine yielded the corresponding pyrazole derivatives 11–13, respectively. On the other hand, interaction of compound 5 with thiourea and/or phenyl isothiocyanate in NaOH/ethanol gave the corresponding pyrimidine and pyridine derivatives 14 and 15, respectively (Scheme 3).

2.2. In-Vitro Anticancer Screening

Doxorubicin, the reference drug used in this study is a drug used in cancer chemotherapy. It is an anthracycline antibiotic, it works by intercalating DNA and inhibition of macromolecular biosynthesis. This inhibits the progression of the enzyme topoisomerase II, which relaxes supercoils in DNA for transcription. Doxorubicin stabilizes the topoisomerase II complex after it has broken the DNA chain for replication, preventing the DNA double helix from being resealed and thereby stopping the process of replication. It is commonly used in the treatment of a wide range of cancers as in acute leukemia’s Hodgkin’s disease, and other lymphomas and cancers of the breast, adrenal cortex, endometrium, lung, ovary, and other sites [34]. The relationship between surviving fraction and drug concentration was plotted; the response parameters calculated was IC50 value, which corresponds to the compound concentration that causes 50% inhibition of cellular viability (Table 1). From Table 1, we can observe that all the tested compounds were found to be equipotent or even more potent than Doxorubicin on the MCF7 cell line with IC50 values ranging from 49.5 to 70.2 μM. The most potent compounds in this study are compound 3 bearing 2-cyanoacrylate moiety (IC50 = 49.5 μM), 3-oxobutanoate derivative 4 (IC50 = 54.8 μM), pyrazole derivative 6 (IC50 = 59.0 μM), pyridine 9 (IC50 = 59.2 μM) and the pyrazole derivative 13 (IC50 = 57.8 μM), and they were found to be more potent than the reference drug Doxorubicin (IC50 = 71.8 μM). On the other hand, the pyrazole derivative 7 and pyrimidine 8 were found to be nearly as potent as the positive control Doxorubicin with IC50 = 70.2, 68.1 μM, respectively. In addition compounds 5, 10, and 11 exhibited a moderate activity with IC50 = 75.3, 76.1, 75.6 μM, respectively. Finally, the least potent are compounds 12 (IC50 = 102.9 μM) and 14, which showed no activity on MCF7 cell line. These results attract the attention of the possible use of the synthesized pyrazole, pyridine and pyrimidine derivatives carrying a biologically active sulfonamide moiety for treatment of breast tumors and these results are in agreement with previous studies done on pyrazole, pyridine and pyrimidine and other sulfonamide derivatives and resulted in compounds with promising anticancer activities [20–25].

3. Experimental Section

3.1. Chemistry

Reagents were obtained from commercial suppliers and were used without purification. Melting points were determined in open capillary tubes using Thermo system FP800 Mettler FP80 central processor (Stuart Scientific, Redhill, UK) supplied with FP81 MBC cell apparatus, and were uncorrected. Elemental analyses (C, H, N) were performed on a Perkin-Elmer 2400 Instrument (Perkin-Elmer, Norwalk, CT, USA). All compounds were within ±0.4% of the theoretical values. Infrared (IR) spectra (KBr disc) were recorded on FT-IR spectrophotometer (Perkin Elmer, Norwalk, CT, USA) at the Research Center, College of Pharmacy, King Saud University, Saudi Arabia.1H- and 13C-NMR spectra were recorded on a Ultra Shield Plus 500 MHz (Bruker, Munich, Germany) spectrometer operating at 500 MHz for proton and 125 MHz for carbon, respectively. The chemical shift values are reported in δ (ppm) relative to the residual solvent peak, the coupling constants (J) are reported in Hertz (Hz).

3.1.1. N-Carbamimidoyl-4-(2,2-cyanovinylamino)benzenesulfonamide (2)

A mixture of sulfaguanidine 1 (2.14 g, 0.01 mol), malononitrile (0.66 g, 0.01 mol), triethylorthoformate (1.48 g, 0.01 mol), and acetic acid (1 mL) in methanol (30 mL) was refluxed for 5 h, the reaction mixture was filtered, the filtered solid was crystallized from ethanol to give 2. Yield%: 85, m.p. = 274.6 °C, IR, cm−1: 3446, 3338, 3205 (NH, NH2), 3100 (CH arom.), 2930, 2846 (CH aliph.), 2212 (CN), 1634 (C=N), 1368, 1151 (SO2). 1H-NMR (DMSO-d6, ppm): 6.1[s, 1H, CH], 6.7[s, 2H, NH2, D2O-exchangeable], 7.5, 7.7[2d, 4H, Ar–H, AB system, J = 7.1 Hz], 8.5[s, 1H, NH–imino, D2O-exchangeable], 11.3[s, 2H, NH + SO2NH, D2O-exchangeable]. 13C-NMR (DMSO-d6, ppm): 56.0, 113.8 (2), 117.7 (2), 126.0 (2), 140.6, 141.2, 155.8, 158.0. Anal. Calcd for C11H10N6O2S (290): C, 45.51; H, 3.47; N, 28.95. Found: C, 45.21; H, 3.80; N, 28.62.

3.1.2. (E)-Ethyl-3-(4-(N-carbamimidoylsulfamoyl)phenylamino)-2-cyanoacrylate (3)

A mixture of sulfaguanidine 1 (2.14 g, 0.01 mol), ethylcyanoacetate (1.13 g, 0.01 mol), triethylorthoformate (1.48 g, 0.01 mol), and acetic acid (1 mL) in methanol (30 mL) was refluxed for 5 h, the reaction mixture was filtered, the filtered solid was crystallized from ethanol to give 3. Yield%: 83, m.p. = 143.6 °C, IR, cm−1: 3433, 3381, 3291 (NH, NH2), 3056 (CH arom.), 2961, 2836 (CH aliph.), 2220 (CN), 1713 (C=O), 1635 (C=N), 1362, 1168 (SO2). 1H-NMR (DMSO-d6, ppm): 1.2[t, 3H, CH3], 4.1[q, 2H, CH2], 5.7[s, 2H, NH2, D2O-exchangeable], 6.5–7.7[m, 5H, Ar–H + CH], 8.5[s, 1H, NH–imino, D2O-exchangeable], 11.0[s, 2H, NH + SO2NH, D2O-exchangeable]. 13C-NMR (DMSO-d6, ppm): 13.8, 61.9, 76.1, 112.1, 117.6 (2), 127.2 (2), 130.6, 141.8, 151.3, 158.0, 164.2. Anal. Calcd for C13H15N5O4S (337): C, 46.28; H, 4.48; N, 20.76. Found: C, 46.51; H, 4.80; N, 20.44.

3.1.3. (E)-Ethyl-2-((4-(N-carbamimidoylsulfamoyl)phenylamino)methylene)-3-oxobutanoate (4)

A mixture of sulfaguanidine 1 (2.14 g, 0.01 mol), ethylacetoacetate (1.30 g, 0.01 mol), triethylorthoformate (1.48 g, 0.01 mol), and acetic acid (1 mL) in methanol (30 mL) was refluxed for 5 h, the reaction mixture was filtered, the filtered solid was crystallized from ethanol to give 4. Yield%: 83, m.p. = 173.9 °C, IR, cm−1: 3433, 3390, 3236 (NH, NH2), 3100 (CH arom.), 2919, 2880 (CH aliph.), 1710, 1699 (2C=O), 1612 (C=N), 1384, 1167 (SO2). 1H-NMR (DMSO-d6, ppm): 1.2[t, 3H, CH3], 2.3[s, 3H, COCH3], 4.1[q, 2H, CH2], 5.6[s, 2H, NH2, D2O-exchangeable], 6.5, 7.4[2d, 4H, Ar–H, AB system, J = 7.3 Hz], 8.4[s, 1H, NH–imino, D2O-exchangeable], 10.2[s, 2H, NH, SO2NH, D2O-exchangeable]. 13C-NMR (DMSO-d6, ppm): 13.9, 24.8, 59.6, 102.7, 118.2 (2), 126.5 (2), 127.2, 148.8, 151.3, 157.7, 169.1, 194.9. Anal. Calcd for C14H18N4O5S (354): C, 47.45; H, 5.12; N, 15.81. Found: C, 47.12; H, 4.80; N, 15.44.

3.1.4. 4-(2-Acetyl-3-oxobut-1-enylamino)-N-carbamimidoylbenzenesulfonamide (5)

A mixture of sulfaguanidine 1 (2.14 g, 0.01 mol), acetylacetone (1.00 g, 0.01 mol), triethylorthoformate (1.48 g, 0.01 mol), and acetic acid (1 mL) in methanol (30 mL) was refluxed for 5 h, the reaction mixture was filtered, the filtered solid was crystallized from ethanol to give 5. Yield%: 81, m.p. = 162.0 °C, IR, cm−1: 3435, 3339, 3132 (NH, NH2), 3099 (CH arom.), 2961, 2834 (CH aliph.), 1721, 1701 (2C=O), 1612 (C=N), 1384, 1156 (SO2). 1H-NMR (DMSO-d6, ppm): 2.4[s, 6H, 2COCH3], 6.6[s, 2H, NH2, D2O-exchangeable], 7.3, 7.7[2d, 4H, Ar–H, AB system, J = 7.0 Hz], 7.9[s, 1H, CH], 8.8[s, 1H, NH–imino, D2O-exchangeable], 12.5[s, 2H, NH, SO2NH, D2O-exchangeable]. 13C-NMR (DMSO-d6, ppm): 23.0 (2), 112.3, 118.1 (2), 127.1 (2), 129.4, 140.2, 142.2, 158.9, 196.1 (2). Anal. Calcd for C13H16N4O4S (324): C, 48.14; H, 4.97; N, 17.27. Found: C, 48.34; H, 4.80; N, 17.47.

3.1.5. N-Carbamimidoyl-4-((3,5-diamino-4H-pyrazol-4-ylidene)methylamino)benzensulfonamide (6)

A mixture of 2 (2.90 g, 0.01 mol) and hydrazine hydrate (0.50 g, 0.01 mol) in dioxane (20 mL) was refluxed for 5 h, the reaction mixture was cooled, poured onto ice water. The precipitated solid product was filtered and crystallized from methanol to give compound 6. Yield%: 76, m.p. = 117.6 °C, IR, cm−1: 3398, 3340, 3276 (NH, NH2), 3066 (CH arom.), 2961, 2836 (CH aliph.), 1618 (C=N), 1384, 1179 (SO2). 1H-NMR (DMSO-d6, ppm): 6.54[s, 2H, NH2, D2O-exchangeable], 6.59[s, 4H, 2NH2-pyrazole, D2O-exchangeable], 6.9–7.4[m, 5H, Ar–H + CH], 8.4[s, 1H, NH–imino, D2O-exchangeable], 9.4[s, 2H, NH, SO2NH, D2O-exchangeable]. 13C-NMR (DMSO-d6, ppm): 112.3, 115.3 (2), 127.2 (2), 130.7, 144.0, 151.3, 157.7, 166.4 (2). Anal. Calcd for C11H14N8O2S (322): C, 40.99; H, 4.38; N, 34.76. Found: C, 40.76; H, 4.67; N, 34.45.

3.1.6. 4-((3-Amino-5-imino-1-methyl-1H-pyrazol-4-(5H)-ylidene)methylamino)-N-carbamimidoyl-benzenesulfonamide (7)

A mixture of 2 (2.90 g, 0.01 mol) and methylhydrazine (0.46 g, 0.01 mol) in dioxane (20 mL) was refluxed for 5 h, the reaction mixture was cooled, poured onto ice water. The precipitated solid products were filtered and crystallized from methanol to give compound 7. Yield%: 89, m.p. = 129.4 °C, IR, cm−1: 3401, 3378, 3312 (NH, NH2), 3026 (CH arom.), 2981, 2860 (CH aliph.), 1595 (C=N), 1368, 1156 (SO2). 1H-NMR (DMSO-d6, ppm): 2.4[s, 3H, CH3], 6.54[s, 2H, NH2, D2O-exchangeable], 6.56[s, 2H, NH2pyrazole, D2O-exchangeable], 7.3–7.5[m, 6H, Ar–H + CH + NH pyrazole], 7.7[s, 1H, NH–imino, D2O-exchangeable], 9.3[s, 2H, NH + SO2NH, D2O-exchangeable]. 13C-NMR (DMSO-d6, ppm): 34.5, 112.3, 115.2 (2), 127.2 (2), 130.7, 139.7, 151.3, 151.4, 157.7, 163.8. Anal. Calcd for C12H16N8O2S (336): C, 42.85; H, 4.79; N, 33.31. Found: C, 42.56; H, 4.98; N, 33.67.

3.1.7. N-Carbamimidoyl-4-(5-cyano-4-oxo-3-phenyl-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)-benzenesulfonamide (8)

A mixture of 2 (2.90 g, 0.01.mol), phenyl isothiocyanate (1.35 g, 0.01 mol) and sodium hydroxide (0.40 g, 0.01 mol) in ethanol (20 mL) was refluxed for 3 h. The reaction mixture was cooled, poured onto ice water, acidified with dilute HCl, then the solid product was filtered and crystallized from dioxane to give 8. Yield%: 88, m.p. = 76.4 °C, IR, cm−1: 3217, 3186, 3109 (NH, NH2), 3030 (CH arom.), 2982, 2861 (CH aliph.), 2193 (CN), 1374, 1199 (SO2), 1291 (C=S). 1H-NMR (DMSO-d6, ppm): 6.9[s, 2H, NH2, D2O-exchangeable], 7.1–7.6[m, 9H, Ar–H], 8.3[s, 1H, CH–pyrimidine], 11.0[s, 2H, NH, SO2NH, D2O-exchangeable]. 13C-NMR (DMSO-d6, ppm): 94.9, 118.1, 121.6 (2), 122.9, 124.9 (2), 128.4 (2), 128.6 (2), 137.7, 138.5, 139.2, 153.5, 160.6, 168.1, 187.7 (C=S). Anal. Calcd for C18H14N6O3S2 (426): C, 50.69; H, 3.31; N, 19.71. Found: C, 50.35; H, 3.66; N, 19.51.

3.1.8. 4-(4-Amino-3-chloro-5-cyano-2-oxopyridin-1(2H)-yl)-N-carbamimidoylbenzenesulfonamide (9)

A mixture of 2 (2.90 g, 0.01.mol) and chloroacetyl chloride (1.13 g, 0.01 mol) in dioxane (20 mL) containing 3 drops of triethylamine was refluxed for 3 h. The reaction mixture was cooled, poured onto ice water and the solid product was filtered and crystallized from ethanol to give 9. Yield%: 79, m.p. = 211.4 °C, IR, cm−1: 3408, 3276, 3204 (NH, NH2), 3100 (CH arom.), 2226 (CN), 1736 (C=O), 1326, 1189 (SO2), 829 (C–Cl). 1H-NMR (DMSO-d6, ppm): 4.4[s, 2H, NH2–pyridine, D2O-exchangeable], 7.5[s, 2H, NH2, D2O-exchangeable], 7.6–8.0[m, 4H, Ar–H], 8.6[s, 1H, CH–pyridine], 11.3[s, 2H, NH, SO2NH, D2O-exchangeable]. 13C-NMR (DMSO-d6, ppm): 91.6, 98.3, 115.9, 118.9 (2), 127.4 (2), 136.6, 138.3, 146.2, 155.7, 166.3, 169.6. Anal. Calcd for C13H11ClN6O3S (366): C, 42.57; H, 3.02; N, 22.91. Found: C, 42.31; H, 3.36; N, 22.67.

3.1.9. N-Carbamimidoyl-4-((4,6-diamino-2-thioxopyrimidin-5(2H)-ylidene)methylamino)-benzenesul-fonamide (10)

A mixture of 2 (2.90 g, 0.01 mol) and thiourea (0.76 g, 0.01 mol) was refluxed for 5 h in ethanol (20 mL) containing sodium ethoxide (0.01 mol). The reaction mixture was cooled, poured onto ice water, acidified with dilute HCl, then the precipitated solid product was filtered and crystallized from methanol to give 10. Yield%: 90, m.p. > 350 °C, IR, cm−1: 3434, 3391, 3309 (NH, NH2), 3088 (CH arom.), 2976, 2819 (CH aliph.), 1384, 1151 (SO2), 1229 (C=S). 1H-NMR (DMSO-d6, ppm): 6.4[s, 2H, NH2, D2O-exchangeable], 6.9[s, 4H, 2NH2–pyrimidine, D2O-exchangeable], 7.9–8.3[m, 5H, Ar–H + CH], 10.3[s, 1H, NH, D2O-exchangeable], 11.7[s, 2H, NH, SO2NH, D2O-exchangeable]. 13C-NMR (DMSO-d6, ppm): 94.1, 116.5 (2), 127.7 (2), 129.3, 138.2, 143.8, 161.8, 163.6 (2), 218.9. Anal. Calcd for C12H14N8O2S2 (366): C, 39.33; H, 3.85; N, 30.58. Found: C, 39.62; H, 3.59; N, 30.23.

3.1.10. N-Carbamimidoyl-4-((3,5-dimethyl-4H-pyrazol-4-ylidene)methylamino)benzensulfonamide (11)

Compound 5 (3.24 g, 0.01 mol) was mixed with hydrazine hydrate (0.50 g, 0.01 mol) in dioxane (20 mL) and refluxed for 5 h, the reaction mixture was cooled, poured onto ice water. The precipitated solid products were filtered and crystallized from methanol to give compound 11. Yield%: 90, m.p. = 113.9 °C, IR, cm−1: 3399, 3368, 3204 (NH, NH2), 3039 (CH arom.), 2944, 2879 (CH aliph.), 1617 (C=N), 1308, 1179 (SO2). 1H-NMR (DMSO-d6, ppm): 2.1[s, 6H, 2CH3], 6.6[s, 2H, NH2, D2O-exchangeable], 7.3–7.6[m, 5H, Ar–H + CH], 9.3[s, 1H, NH, D2O-exchangeable], 11.1[s, 2H, NH–imino + SO2NH, D2O-exchangeable]. 13C-NMR (DMSO-d6, ppm): 23.0 (2), 103.1, 112.3 (2), 127.2 (2), 130.2, 130.7, 151.3, 157.7, 167.2 (2). Anal. Calcd for C13H16N6O2S (320): C, 48.74; H, 5.03; N, 26.23. Found: C, 48.99; H, 5.41; N, 26.01.

3.1.11. N-Carbamimidoyl-4-((1,3,5-trimethyl-1H-pyrazol-4-yl)methyleneamino)benzenesulfonamide (12)

Compound 5 (3.24 g, 0.01 mol) was mixed with methylhydrazine (0.4 g, 0.01 mol) in dioxane (20 mL) and refluxed for 5 h, the reaction mixture was cooled, poured onto ice water. The precipitated solid product was filtered and crystallized from methanol to give compound 12. Yield%: 76, m.p. = 171.8 °C, IR, cm−1: 3394, 3351, 3391 (NH, NH2), 3100 (CH arom.), 2976, 2852 (CH aliph.), 1620 (C=N), 1309, 1178 (SO2). 1H-NMR (DMSO-d6, ppm): 2.5[s, 6H, 2CH3], 3.4[s, 3H, NCH3], 5.6[s, 2H, NH2, D2O-exchangeable], 6.5–7.3[m, 4H, Ar–H + CH], 7.4[s, 1H, NH–imino, D2O-exchangeable], 8.9[s, 2H, NH + SO2NH, D2O-exchangeable]. 13C-NMR (DMSO-d6, ppm): 13.2, 17.3, 40.0, 112.3, 125.4 (2), 127.2 (2), 136.7, 146.8, 151.3, 157.7, 161.4, 177.8. Anal. Calcd for C14H18N6O2S (334): C, 50.28; H, 5.43; N, 25.13. Found: C, 50.67; H, 5.08; N, 25.36.

3.1.12. N-Carbamimidoyl-4-((3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)methyleneamino)-benzenesulf-onamide (13)

Compound 5 (3.24 g, 0.01 mol) was mixed with phenylhydrazine (1.08 g, 0.01 mol) in dioxane (20 mL) and refluxed for 5 h, the reaction mixture was cooled, poured onto ice water. The precipitated solid product was filtered and crystallized from methanol to give compound 13. Yield%: 87, m.p. = 100.8 °C, IR, cm−1: 3386, 3320, 3220 (NH, NH2), 3099 (CH arom.), 2955, 2836 (CH aliph.), 1598 (C=N), 1384, 1130 (SO2). 1H-NMR (DMSO-d6, ppm): 2.5[s, 6H, 2CH3], 6.0[s, 2H, NH2, D2O-exchangeable], 6.5–7.7[m, 9H, Ar–H+], 9.7[s, 1H, NH–imino, D2O-exchangeable], 9.9[s, 2H, NH + SO2NH, D2O-exchangeable]. 13C-NMR (DMSO-d6, ppm): 12.1 (CH3), 13.2 (CH3), 117.3, 121.3 (2), 124.0 (2), 126.6, 127.3 (2), 128.6 (2), 139.0, 139.6, 147.4, 150.8, 157.6, 158.0, 172.1. Anal. Calcd for C19H20N6O2S (396): C, 57.56; H, 5.08; N, 21.20. Found: C, 57.36; H, 5.24; N, 21.59.

3.1.13. N-Carbamimidoyl-4-((4,6-dimethyl-2-thioxopyrimidin-5(2H)-ylidene)methylamino) benzene-sulfonamide (14)

A mixture of 5 (3.24 g, 0.01 mol) and thiourea (0.76 g, 0.01 mol) was refluxed for 5 h in ethanol (20 mL) containing sodium ethoxide (0.01 mol). The reaction mixture was cooled, poured onto ice water, acidified with dilute HCl, then the precipitated solid product was filtered and crystallized from methanol to give 14. Yield%: 89, m.p. > 350 °C, IR, cm−1: 3427, 3393, 3286 (NH, NH2), 3076 (CH arom.), 2971, 2876 (CH aliph.), 1636 (C=N), 1386, 1161 (SO2), 1246 (C=S). 1H-NMR (DMSO-d6, ppm): 0.8[s, 6H, 2CH3], 6.4[s, 2H, NH2, D2O-exchangeable], 7.2–7.4[m, 5H, Ar–H + CH], 8.7[s, 1H, NH–imino, D2O-exchangeable], 9.4[s, 2H, NH, SO2NH, D2O-exchangeable]. 13C-NMR (DMSO-d6, ppm): 19.8 (2), 86.9, 114.2 (2), 127.4, 128.6 (2), 134.1, 145.3, 162.0 (2), 173.2, 209.0 (C=S). Anal. Calcd for C14H16N6O2S2 (364): C, 46.14; H, 4.43; N, 23.06. Found: C, 45.89; H, 4.78; N, 23.41.

3.1.14. (E)-4-(5-Acetyl-4-hydroxy-2-(phenylimino)pyridine-1(2H)-yl)-N-cabamimidoylbenzenesul-fonamide (15)

A mixture of 5 (3.24 g, 0.01 mol), phenyl isothiocyanate (1.35 g, 0.01 mol) and sodium hydroxide (0.4 g, 0.01 mol) in ethanol (20 mL) was refluxed for 3 h. The reaction mixture was cooled, poured onto ice water, acidified with dilute HCl, then the solid product was filtered and crystallized from dioxane to give 15. Yield%: 79, m.p. = 66.6 °C, IR, cm−1: 3436 (OH), 3208, 3186, 3121 (NH, NH2), 3030 (CH arom.), 2982, 2861 (CH aliph.), 1706 (C=O), 1596 (C=N), 1374, 1160 (SO2). 1H-NMR (DMSO-d6, ppm): 2.4[s, 3H, COCH3], 4.5[s, 1H, OH], 6.9[s, 2H, NH2, D2O-exchangeable], 7.1–7.4[m, 9H, Ar–H], 9.4[s, 1H, NH–imino, D2O-exchangeable], 10.8[s, 1H, SO2NH, D2O-exchangeable]. 13C-NMR (DMSO-d6, ppm): 26.2, 67.1, 118.1 (2), 121.6, 122.9 (2), 124.5, 128.6 (2), 128.9, 130.8 (2), 137.8, 142.4, 153.5, 164.9, 169.1, 171.4, 199.3. Anal. Calcd for C20H19N5O4S (425): C, 56.46; H, 4.50; N, 16.46. Found: C, 56.11; H, 4.89; N, 16.80.

3.2. In-Vitro Anticancer Screening

The human tumor cell line (MCF7) was available at the National Cancer Institute, Cairo, Egypt. The antitumor activity of the newly synthesized compounds was measured using the sulfo-rhodamine-B stain (SRB) assay by the method of Skehan et al. (1990) [35,36]. The cell lines were grown in RPMI 1640 medium containing 10% fetal bovine serum and 2 mM l-glutamine. Cells were plated in 96-multiwell plates (104 cells/well), after cell inoculation, the micro titer plates were incubated at 37 °C, 5% CO2, 95% air and 100% relative humidity for 24 h prior to addition of experimental drugs to allow attachment of cell to the wall of the plate. After 24 h, cell line was fixed in situ with TCA (trichloro acetic acid). Tested compounds 3–14 were dissolved in DMSO and diluted with saline to the appropriate volume and maintained in RPMI 1640 medium. Different concentrations of the compounds under test (5, 12.5, 25, and 50 μM) were added to the cell monolayer. Triplicate wells were prepared for each individual dose. Monolayer cells were incubated with the compounds for 48 h at 37 °C and in atmosphere of 5% CO2. After 48 h, cells were fixed in situ by the gentle addition of 50 μL of cold 30% (w/v) TCA (final concentration, 10% TCA) and incubated for 60 min at 4 °C. The supernatant was discarded; the plates were washed five times with tap water and air dried. Sulforhodamine B (SRB) solution (50 μL) at 0.4% (w/v) in 1% acetic acid was added to each of the wells, and plates were incubated for 20 min at room temperature. After staining, unbounded dye was removed by four washes with 1% acetic acid, and attached stain was recovered with Tris-EDTA buffer. Color intensity was measured in an ELISA reader (Gmbh, Viesbaden, Germany). The relation between surviving fraction and drug concentration was plotted to get the survival curve of each tumor cell line after the specified time. The concentration required for 50% inhibition of cell viability (IC50) was calculated and compared with the reference drug Doxorubicin and the results are given in (Table 1).

4. Conclusions

We report in this work the synthesis of a novel series of 4-(substituted)-N-(guanidinyl)benzenesulfonamides bearing a biologically active pyrazole, pyrimidine and pyridine moieties through simple and convenient routes These new derivatives were evaluated for their anticancer activity against human tumor breast cell line (MCF7). It was found that the most potent compounds in this study were the corresponding 2-cyanoacrylate 3, 3-oxobutanoate 4, pyrazole 6, pyridine 9 and pyrazole 13.

Acknowledgments

The authors would like to extend their sincere appreciation to the Deanship of Scientific Research at King Saud University (Riyadh, Saudi Arabia) for its funding of this research through the Research Group Project No. RGP-VPP-302.

Conflicts of Interest

The authors declare no conflict of interest.
  • Author ContributionsM.M.G. suggested the research idea and contributed in the experimental work. M.G.E.-G. contributed in the experimental work and in writing the paper. M.S.A. contributed in the experimental work and the biological activity.

References

  1. Hooley, R.J.; Scoutt, L.M.; Philpotts, L.E. Breast ultrasonography: State of the art. Radiology 2013, 268, 642–659. [Google Scholar]
  2. Gizzo, S.; Saccardi, C.; Patrelli, T.S.; Berretta, R.; Capobianco, G.; di Gangi, S.; Vacilotto, A.; Bertocco, A.; Noventa, M.; Ancona, E.; et al. Update on raloxifene: Mechanism of action, clinical efficacy, adverse effects, and contraindications. Obstet. Gynecol. Surv 2013, 68, 467–481. [Google Scholar]
  3. Piva, R.; Spandidos, D.A.; Gambari, R. From microRNA functions to microRNA therapeutics: Novel targets and novel drugs in breast cancer research and treatment. Int. J. Oncol 2013, 43, 985–994. [Google Scholar]
  4. Jackson, C.; Browell, D.; Gautrey, H.; Tyson-Capper, A. Clinical significance of HER-2 splice variants in breast cancer progression and drug resistance. Int. J. Cell Biol 2013, 2013, 973584:1–973584:8. [Google Scholar]
  5. Reimers, L.; Crew, K.D. Tamoxifenvs raloxifenevs exemestane for chemoprevention. Curr. Breast Cancer Rep 2012, 4, 207–215. [Google Scholar]
  6. Silber, J.H.; Rosenbaum, P.R.; Clark, A.S.; Giantonio, B.J.; Ross, R.N.; Teng, Y.; Wang, M.; Niknam, B.A.; Ludwig, J.M.; Wang, W.; et al. Characteristics associated with differences in survival among black and white women with breast cancer. J. Am. Med. Assoc 2013, 310, 389–397. [Google Scholar]
  7. Chakrabarti, S.; Karmakar, R.; Barui, G.; Maity, P.K.; Bandyopadhyay, A.; Roy, A. Prevalence of known prognostic factors in female breast carcinoma including oestrogen receptor, progesterone receptor and Her-2/neu status—A study in a tertiary care centre. J. Indian Med. Assoc 2012, 110, 876–879. [Google Scholar]
  8. Thumar, N.J.; Patel, M.P. Synthesis, characterization, and antimicrobial evaluation of carbostyril derivatives of 1H-pyrazole. Saudi Pharm. J 2011, 19, 75–83. [Google Scholar]
  9. Kumar, V.; Kaur, K.; Gupta, G.K.; Gupta, A.K.; Kumar, S. Developments in synthesis of the anti-inflammatory drug, celecoxib: A review. Recent Pat. Inflamm. Allergy Drug Discov 2013, 7, 124–134. [Google Scholar]
  10. Zaninetti, R.; Cortese, S.V.; Aprile, S.; Massarotti, A.; Canonico, P.L.; Sorba, G.; Grosa, G.; Genazzani, A.A.; Pirali, T. A concise synthesis of pyrazole analogues of combretastatin A1 as potent anti-tubulin agents. Chem. Med. Chem 2013, 8, 633–643. [Google Scholar]
  11. Ibrahim, H.M.; Behbehani, H.; Elnagdi, M.H. Approaches towards the synthesis of a novel class of 2-amino-5-arylazonicotinate, pyridazinone and pyrido[2,3-d]pyrimidine derivatives as potent antimicrobial agents. Chem. Cent. J 2013, 7, 123:1–123:16. [Google Scholar]
  12. Ivanov, M.A.; Aleksandrova, L.A. Bicyclic furano[2,3-d] derivatives of pyrimidine nucleosides—Synthesis and antiviral properties. Bioorganicheskaia Khimiia 2013, 39, 26–45. [Google Scholar]
  13. Singh, K.; Kaur, H.; Chibale, K.; Balzarini, J. Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies. Eur. J. Med. Chem 2013, 66, 314–323. [Google Scholar]
  14. Shaquiquzzaman, M.; Khan, S.A.; Amir, M.; Alam, M.M. Synthesis, anticonvulsant and neurotoxicity evaluation of some new pyrimidine-5-carbonitrile derivatives. Saudi Pharm. J 2012, 20, 149–154. [Google Scholar]
  15. Lauria, A.; Patella, C.; Abbate, I.; Martorana, A.; Almerico, A.M. An unexpected Dimroth rearrangement leading to annelatedthieno[3,2-d][1,2,3]triazolo[1,5-a]pyrimidines with potent antitumor activity. Eur. J. Med. Chem 2013, 65, 381–388. [Google Scholar]
  16. Rezende, V.M.; Rivellis, A.J.; Gomes, M.M.; Dörr, F.A.; Novaes, M.M.; Nardinelli, L.; Costa, A.L.; Chamone, D.A.; Bendit, I. Determination of serum levels of imatinibmesylate in patients with chronic myeloid leukemia: Validation and application of a new analytical method to monitor treatment compliance. Rev. Bras. Hematol. Hemoter 2013, 35, 103–108. [Google Scholar]
  17. Wei, X.; Zhou, D.; Wang, H.; Ding, N.; Cui, X.X.; Wang, H.; Verano, M.; Zhang, K.; Conney, A.H.; Zheng, X.; et al. Effects of pyridine analogs of curcumin on growth, apoptosis and NF-κB activity in prostate cancer PC-3 cells. Anticancer Res 2013, 33, 1343–1350. [Google Scholar]
  18. Wang, X.M.; Xu, J.; Li, Y.P.; Li, H.; Jiang, C.S.; Yang, G.D.; Lu, S.M.; Zhang, S.Q. Synthesis and anticancer activity evaluation of a series of [1,2,4]triazolo[1,5-a]pyridinylpyridines in vitro and in vivo. Eur. J. Med. Chem. 2013, 67C, 243–251. [Google Scholar]
  19. Li, L.; Du, K.; Wang, Y.; Jia, H.; Hou, X.; Chao, H.; Ji, L. Self-activating nuclease and anticancer activities of copper(ii) complexes with aryl-modified 2,6-di(thiazol-2-yl)pyridine. Dalton Trans 2013, 42, 11576–11588. [Google Scholar]
  20. AlSaid, M.S.; El-Gazzar, M.G.; Ghorab, M.M. Anticancer activity of novel thiophenes containing a biological active diphenylsulfone, diazepin, piperidine, oxazepine, acryladehyde and sulfonamide moieties. Drug Res. (Stuttg) 2013, 63, 263–269. [Google Scholar]
  21. Al-Dosari, M.S.; Ghorab, M.M.; AlSaid, M.S.; Nissan, Y.M. Discovering some novel 7-chloroquinolines carrying a biologically active benzenesulfonamide moiety as a new class of anticancer agents. Chem. Pharm. Bull 2013, 61, 50–58. [Google Scholar]
  22. AlSaid, M.S.; El-Gazzar, M.G.; Ghorab, M.M. In-vitro cytotoxic and radiosensitizing evaluation of novel 2-pyridone, isoquinoline, chromene and chromenopyridone derivatives. Eur. J. Chem 2012, 3, 228–234. [Google Scholar]
  23. El-Said, M.S.; El-Gazzar, M.G.; Al-Dosari, M.S.; Ghorab, M.M. Synthesis, anticancer activity and radiosensitizing: Evaluation of some new 2-pyridone derivatives. Arzneimittelforschung 2012, 62, 149–156. [Google Scholar]
  24. Ghorab, M.M.; Ragab, F.A.; Heiba, H.I.; Youssef, H.A.; El-Gazzar, M.G. Synthesis of novel pyrazole and pyrimidine derivatives bearing sulfonamide moiety as antitumor and radiosensitizing agents. Med. Chem. Res 2012, 21, 1376–1383. [Google Scholar]
  25. Ghorab, M.M.; Ragab, F.A.; Heiba, H.I.; El-Gazzar, M.G.; El-Gazzar, M.G. Synthesis, in vitro anticancer screening and radiosensitizing evaluation of some new 4-[3-(substituted)thioureido]-N-(quinoxalin-2-yl)-benzenesulfonamide derivatives. Acta Pharm 2011, 61, 415–425. [Google Scholar]
  26. Brożewicz, K.; Sławiński, J. 1-(2-Mercaptobenzenesulfonyl)-3-hydroxyguanidines—Novel potent antiproliferatives, synthesis and in vitro biological activity. Eur. J. Med. Chem 2012, 55, 384–394. [Google Scholar]
  27. Calderón-Montaño, J.M.; Burgos-Morón, E.; Orta, M.L.; Pastor, N.; Perez-Guerrero, C.; Austin, C.A.; Mateos, S.; López-Lázaro, M. Guanidine-reactive agent phenylglyoxal induces DNA damage and cancer cell death. Pharmacol. Rep 2012, 64, 1515–1525. [Google Scholar]
  28. Duo, J.; Ma, Y.; Wang, G.; Han, X.; Zhang, C. Metformin synergistically enhances antitumor activity of histone deacetylase inhibitor trichostatina against osteosarcoma cell line. DNA Cell Biol 2013, 32, 156–164. [Google Scholar]
  29. Würth, R.; Pattarozzi, A.; Gatti, M.; Bajetto, A.; Corsaro, A.; Parodi, A.; Sirito, R.; Massollo, M.; Marini, C.; Zona, G.; et al. Metformin selectively affects human glioblastoma tumor-initiating cell viability: A role for metformin-induced inhibition of Akt. Cell Cycle 2013, 12, 145–156. [Google Scholar]
  30. Sinnett-Smith, J.; Kisfalvi, K.; Kui, R.; Rozengurt, E. Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: Dependence on glucose concentration and role of AMPK. Biochem. Biophys. Res. Commun 2013, 430, 352–357. [Google Scholar]
  31. Furukawa, K.; Uwagawa, T.; Iwase, R.; Haruki, K.; Fujiwara, Y.; Gocho, T.; Shiba, H.; Misawa, T.; Yanaga, K. Prognostic factors of unresectable pancreatic cancer treated with nafamostatmesilate combined with gemcitabine chemotherapy. Anticancer Res 2012, 32, 5121–5126. [Google Scholar]
  32. Georgopoulos, S.; Mastorakos, D.; Kondi-Pafiti, A.; Katsenis, K.; Arkadopoulos, N.; Kannas, D.; Archontaki, M.; Vestarchis, N.; Kokkalis, G. Hydroxyzine, cimetidine and vitamin C in reducing skin flap necrosis in ischemia-reperfusion injury in rats: A comparative study. J. BUON 2012, 17, 377–382. [Google Scholar]
  33. Ozeki, T.; Natori, T. The specific inhibition of HepG2 cells proliferation by apoptosis induced by gabexatemesilate. Int. J. Clin. Exp. Pathol 2010, 3, 710–717. [Google Scholar]
  34. Fornari, F.A.; Randolph, J.K.; Yalowich, J.C.; Ritke, M.K.; Gewirtz, D.A. Interference by Doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol. Pharmacol 1994, 45, 649–656. [Google Scholar]
  35. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J.T.; Bokesch, H.; Kenney, S.; Boyd, M.R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst 1990, 82, 1107–1112. [Google Scholar]
  36. Rubinstein, L.V.; Shoemaker, R.H.; Paull, K.D.; Simon, R.M.; Tosini, S.; Skehan, P.; Scudiero, D.A.; Monks, A.; Boyd, M.R. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay vs. a protein assay against a diverse panel of human tumor cell lines. J. Natl. Cancer Inst 1990, 82, 1113–1118. [Google Scholar]
Ijms 15 05582f1 1024
Figure 1. Some commercially available guanidine containing drugs.
Figure 1. Some commercially available guanidine containing drugs.
Ijms 15 05582f1
Ijms 15 05582f2 1024
Scheme 1. Synthetic pathways for compounds 2–5.
Scheme 1. Synthetic pathways for compounds 2–5.
Ijms 15 05582f2
Ijms 15 05582f3 1024
Scheme 2. Synthetic pathways for compounds 6–10.
Scheme 2. Synthetic pathways for compounds 6–10.
Ijms 15 05582f3
Ijms 15 05582f4 1024
Scheme 3. Synthetic pathways for compounds 11–15.
Scheme 3. Synthetic pathways for compounds 11–15.
Ijms 15 05582f4
Table
Table 1. In-vitro anticancer screening of compounds 3–14 against human breast cell line (MCF7).
Table 1. In-vitro anticancer screening of compounds 3–14 against human breast cell line (MCF7).
Compound No.IC50 (μg/mL)IC50 (μM)
316.749.5
419.454.8
524.475.3
619.059.0
723.670.2
829.068.1
921.759.2
1023.376.1
1124.275.6
1234.4102.9
1322.957.8
14NANA
Doxorubicin39.071.8

Share and Cite

MDPI and ACS Style

Ghorab, M.M.; El-Gazzar, M.G.; Alsaid, M.S. Synthesis and Anti-Breast Cancer Evaluation of Novel N-(Guanidinyl)benzenesulfonamides. Int. J. Mol. Sci. 2014, 15, 5582-5595. https://doi.org/10.3390/ijms15045582

AMA Style

Ghorab MM, El-Gazzar MG, Alsaid MS. Synthesis and Anti-Breast Cancer Evaluation of Novel N-(Guanidinyl)benzenesulfonamides. International Journal of Molecular Sciences. 2014; 15(4):5582-5595. https://doi.org/10.3390/ijms15045582

Chicago/Turabian Style

Ghorab, Mostafa M., Marwa G. El-Gazzar, and Mansour S. Alsaid. 2014. "Synthesis and Anti-Breast Cancer Evaluation of Novel N-(Guanidinyl)benzenesulfonamides" International Journal of Molecular Sciences 15, no. 4: 5582-5595. https://doi.org/10.3390/ijms15045582

Article Metrics

Back to TopTop